| Literature DB >> 31805722 |
Kun-Ming Chan1, Yu-Chao Wang1, Tsung-Han Wu1, Chih-Hsien Cheng1, Chen-Fang Lee1, Ting-Jung Wu1, Hong-Shiue Chou1, Wei-Chen Lee1.
Abstract
Background: Organ demand for liver transplantation (LT) is constantly increasing. Split liver transplantation (SPLT) is an ideal option for increasing the number of available liver grafts for transplantation and ameliorating organ shortage to a certain degree. However, SPLT for two adult recipients is still not broadly applied.Entities:
Keywords: adult recipient; graft weight; outcome; risk factor; split liver transplantation
Year: 2019 PMID: 31805722 PMCID: PMC6947574 DOI: 10.3390/jcm8122095
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Illustration of split liver transplantation. (A) The right and left hemi-liver grafts were completely separated on the back table. (B) Right hemi-liver graft implantation. (C) Left hemi-liver graft implantation.
The clinical characteristics of deceased donors.
| Total Donors | |
|---|---|
| Male:female | 39:15 |
| Age (years) | 27 (15–53) |
| Body height (cm) | 170 (150–187) |
| Body weight (kg) | 67 (45–97) |
| Estimated standard liver volume (mL) | 1274 (929–1533) |
| Actual liver graft weight (gm) * | 1380 (990–2100) |
| Discrepancy of graft estimation (%) | –4.5% (–32.8%–37.1%) |
| Hospital stay (days) | 5 (1–36) |
| CPCR history | 9 |
| Cause of brain death | |
| CVA | 29 |
| Traumatic head injury | 17 |
| Others | 8 |
| Graft recovery | |
| In the institute ( | |
| Two hemi-live graft | 41 (82 hemi-liver graft) |
| One hemi-liver graft | 4 hemi-liver graft |
| Other institute ( | |
| Two hemi-liver graft | 5 (10 hemi-liver graft) |
| One hemi-liver graft | 4 hemi-liver graft |
* Actual liver weights were the sum of left and right liver graft weight; CPCR, Cardiopulmonary Cerebral Resuscitation; CVA, cerebrovascular accident.
Analysis of risk factor for early mortality.
| Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|
| Characteristics | Yes, | No, | OR (95% CI) | ||
| Donor factors | |||||
| Age, median (range) | 32 (15–49) | 27 (15–53) | 0.611 | — | |
| Sex (Male:Female) | 13:8 | 62:17 | 0.119 | — | |
| Cause of brain death | |||||
| CVA | 16 (76.2) | 58 (73.4) | 0.848 | — | |
| Traumatic head injury | 4 (19.0) | 13 (16.5) | |||
| Others | 1 (4.8) | 8 (10.1) | |||
| Hospital stay (days) | 5 (1–36) | 5 (1–36) | 0.835 | — | |
| Graft factors | |||||
| Graft type | 0.004 | 1.30 (0.31–5.38) | 0.710 | ||
| Left hemi-liver | 16 (76.2) | 32 (40.5) | |||
| Right hemi-liver | 5 (23.8) | 47 (59.5) | |||
| Graft weight (gm) | 520 (335–1100) | 695 (350–1500) | 0.004 | 0.99 (0.98–0.99) | 0.036 |
| Cold ischemia time (min) | 474 (102–763) | 337 (69–779) | 0.207 | — | |
| Warm ischemia time (min) | 39 (31–57) | 45 (27–65) | 0.116 | — | |
| Recipient factors | |||||
| Age, median (range) | 49 (39–65) | 51 (33–65) | 0.929 | — | |
| Sex (Male:Female) | 12:9 | 51:28 | 0.532 | — | |
| Main indication of transplantation | 0.353 | — | |||
| Alcoholic Liver cirrhosis | 3 (14.3) | 20 (25.3) | |||
| Virus-related liver cirrhosis | 7 (33.3) | 24 (30.4) | |||
| Hepatocellular carcinoma | 5 (23.8) | 24 (30.4) | |||
| Others | 6 (28.6) | 11 (13.9) | |||
| Viral hepatitis | 0.902 | — | |||
| HBV | 10 (47.6) | 35 (44.3) | |||
| HCV | 4 (19.0) | 15 (19.0) | |||
| HBV + HCV | 0 | 2 (2.5) | |||
| None | 7 (33.3) | 27 (34.2) | |||
| Child classification | 0.220 | — | |||
| A, B | 13 (61.9) | 37 (46.8) | |||
| C | 8 (38.1) | 42 (53.2) | |||
| Chronic kidney disease staging | 0.462 | — | |||
| Grade 1,2 | 14 (66.7) | 59 (74.7) | |||
| Grade 3,4,5 | 7 (33.3) | 20 (25.3) | |||
| Hemodialysis before transplantation | 3 (14.3) | 5 (6.3) | 0.232 | — | |
| MELD score, median (range) | 18 (7–42) | 19 (7–45) | 0.842 | — | |
| Biochemical factors | |||||
| Sodium (Na, ng/mL) | 137 (121–151) | 138 (124–152) | 0.176 | — | |
| Total Bilirubin (ng/mL) | 3.7 (0.5–34.3) | 4.1 (0.5–38.2) | 0.956 | — | |
| Neutrophil-lymphocyte ratio | 4.4 (2.3–47.0) | 5.3 (0.9–169.7) | 0.545 | — | |
| GRWR | 1.0 (0.8–2.0) | 1.1 (0.6–2.0) | 0.054 | 4.14 (0.27–62.90) | 0.305 |
| Transplantation factors | |||||
| Transplantation period | 0.362 | — | |||
| Before 2008 | 8 (38.1) | 22 (27.8) | |||
| After 2008 (2008/01/01) | 13 (61.9) | 57 (72.2) | |||
| Time of Transplantation | 0.588 | — | |||
| Daytime transplantation | 18 (85.7) | 71 (89.9) | |||
| Nighttime transplantation | 3 (14.3) | 8 (10.1) | |||
| Total operation time (hours) | 10.9 (5.1–18.0) | 10.2 (5.6–15.5) | 0.681 | — | |
| Operative blood loss (L) | 3.0 (0.2–18.7) | 2.0 (0.1–19.0) | 0.130 | — | |
HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease; GRWR, graft-recipient weight ratio; OR, odds ratio; CI, confidence interval.
Analysis of risk factor for 1-year mortality.
| Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|
| Characteristics | Yes, | No, | OR (95% CI) | ||
| Donor factors | |||||
| Age, median (range) | 32 (15–52) | 27 (15–53) | 0.482 | — | |
| Sex (Male:Female) | 20:11 | 46:12 | 0.129 | — | |
| Cause of brain death | 0.641 | — | |||
| CVA | 24 (77.4) | 41 (70.7) | |||
| Traumatic head injury | 6 (19.4) | 11 (19.0) | |||
| Others | 1 (3.2) | 6 (10.3) | |||
| Hospital stay (days) | 5 (1–36) | 5 (1–18) | 0.706 | — | |
| Graft factors | |||||
| Graft type | <0.001 | 1.64 (0.38–7.10) | 0.507 | ||
| Left hemi-liver | 23 (74.2) | 20 (34.5) | |||
| Right hemi-liver | 8 (25.8) | 38 (65.5) | |||
| Graft weight (gm) | 520 (335–1100) | 745 (390–1500) | <0.001 | 0.99 (0.98–1.00) | 0.070 |
| Cold ischemia time (min) | 513 (102–763) | 271 (69–779) | 0.039 | 1.00 (1.00–1.01) | 0.069 |
| Warm ischemia time (min) | 40 (31–58) | 45 (27–65) | 0.262 | — | |
| Recipient factors | |||||
| Age, median (range) | 50 (39–65) | 51 (33–65) | 0.368 | — | |
| Sex (Male:Female) | 18:13 | 39:19 | 0.390 | — | |
| Main indication of transplantation | 0.173 | — | |||
| Alcoholic Liver cirrhosis | 6 (19.4) | 14 (24.1) | |||
| Virus-related liver cirrhosis | 11 (35.5) | 18 (31.0) | |||
| Hepatocellular carcinoma | 6 (19.4) | 20 (34.5) | |||
| Others | 8 (25.8) | 6 (10.3) | |||
| Viral hepatitis | 0.409 | — | |||
| HBV | 16 (51.6) | 25 (43.1) | |||
| HCV | 4 (12.9) | 14 (24.1) | |||
| HBV + HCV | 0 | 2 (3.4) | |||
| None | 11 (35.5) | 17 (29.3) | |||
| Child classification | 0.885 | — | |||
| A, B | 15 (48.4) | 29 (50.0) | |||
| C | 16 (51.6) | 29 (50.0) | |||
| Chronic kidney disease staging | 0.312 | — | |||
| Grade 1, 2 | 21 (67.7) | 45 (77.6) | |||
| Grade 3, 4, 5 | 10 (32.3) | 13 (22.4) | |||
| Hemodialysis before transplantation | 3 (9.7) | 3 (5.2) | 0.419 | — | |
| MELD score, median (range) | 18 (7–42) | 19 (7–45) | 0.887 | — | |
| Biochemical factors | |||||
| Sodium (Na, ng/mL) | 137 (121–151) | 138 (124–152) | 0.455 | — | |
| Total Bilirubin (ng/mL) | 4.1 (0.5–34.3) | 4.6 (0.5–38.2) | 0.925 | — | |
| Neutrophil-lymphocyte ratio | 4.4 (1.6–169.7) | 5.4 (0.9–46.0) | 0.535 | — | |
| GRWR | 1.0 (0.7–2.0) | 1.1 (0.6–2.0) | 0.007 | 3.33 (0.21–51.53) | 0.388 |
| Transplantation factors | |||||
| Transplantation period | 0.832 | — | |||
| Before 2008 | 10 (32.3) | 20 (34.5) | |||
| After 2008 (2008/01/01) | 21 (67.7) | 38 (65.5) | |||
| Time of Transplantation | 0.574 | — | |||
| Daytime transplantation | 28 (90.3) | 50 (86.2) | |||
| Nighttime transplantation | 3 (9.7) | 8 (13.8) | |||
| Total operation time (hours) | 10.8 (5.1–18.0) | 10.3 (6.4–15.5) | 0.856 | — | |
| Operative blood loss (L) | 3.0 (0.2–18.7) | 2.0 (0.1–19.0) | 0.210 | — | |
HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease; GRWR, graft-recipient weight ratio; OR, odds ratio; CI, confidence interval
Recipients transplanted with a hemi-liver graft weighing <580 g and who encountered major events leading to early mortality.
| Recipient No. | Age/sex | Indication of Transplantation | MELD | Hemi-liver graft | Graft weight (g)/GRWR (%) | Major events | Mortality (Days) |
|---|---|---|---|---|---|---|---|
| 85 | 48/F | Autoimmune hepatitis | 38 | Left | 460/0.79 | Graft dysfunction, infection | 61 |
| 111 | 49/M | HBV, ESLD | 21 | Left | 425/0.85 | Graft dysfunction, infection | 26 |
| 126 | 39/M | HBV, ESLD | 18 | Left | 520/0.84 | Acute renal failure | 9 |
| 209 | 65/F | HCV, ESLD | 11 | Left | 410/0.85 | Graft dysfunction, infection | 13 |
| 221 | 62/F | Wilson‘s disease | 17 | Left | 520/0.91 | Graft dysfunction, infection | 7 |
| 254 | 50/M | HBV, HCC | 9 | Left | 525/1.17 | Graft dysfunction, infection | 32 |
| 342 | 54/M | HBV, HCC | 11 | Left | 480/0.81 | Antibody mediated Rejection | 18 |
| 399 | 48/M | Alcoholic liver cirrhosis | 16 | Left | 335/0.76 | Pneumonia | 64 |
| 426 | 49/M | HBV, HCC | 17 | Right | 550/0.95 | Antibody mediated rejection | 9 |
| 537 | 47/M | HBV, ESLD | 42 | Right | 570/0.97 | Graft dysfunction, infection | 11 |
| 538 | 45/F | PBC | 17 | Left | 450/0.90 | Graft dysfunction, infection | 31 |
| 790 | 43/F | Alcoholic liver cirrhosis | 27 | Left | 430/0.96 | Acute graft versus host disease | 46 |
| 848 | 60/F | HCV, HCC | 7 | Left | 520/0.81 | HCV relapse | 81 |
| 978 | 61/F | HCV, HCC | 28 | Left | 390/0.86 | Intra-operative massive bleeding | 1 |
| 1033 | 54/F | PBC | 29 | Left | 520/1.18 | Intracranial hemorrhage | 68 |
MELD, Model for End-stage Liver Disease; GRWR, graft recipient weight ratio; F, female; M, male; HBV, hepatitis B virus; HCV, hepatitis C virus; ESLD, end-stage liver disease; PBC, primary biliary cirrhosis; HCC, hepatocellular carcinoma.
Figure 2Comparison of Kaplan–Meier survival curves between patients who underwent liver transplantation (LT) and patients in the wait-list. Split liver transplantation (SPLT) remarkably provided a survival benefit for patients (p < 0.0001). No significant difference between whole liver transplantation (WLT) and SPLT (p = 0.198).
Clinical features of patients on the wait-list and liver transplantation.
| Waitlist | SPLT | WLT | ||
|---|---|---|---|---|
| Age (years), median (range) | 53 (25–66) | 50 (33–65) | 53 (19–65) | 0.285 |
| Male: female | 750:245 | 63:37 | 132:33 | 0.006 |
| Hepatitis status | 0.061 | |||
| HBV | 476 (47.8) | 45 (45.0) | 93 (56.3) | |
| HCV | 167 (16.8) | 19 (19.0) | 30 (18.2) | |
| HBV + HCV | 35 (3.5) | 2 (2.0) | 9 (5.5) | |
| None | 317 (31.9) | 34 (34.0) | 33 (20) | |
| Main indications for LT | 0.116 | |||
| Acute hepatic failure | 48 (4.8) | 1 (1.0) | 2 (1.2) | |
| Hepatocellular carcinoma | 261 (26.2) | 29 (29.0) | 55 (33.4) | |
| Viral cirrhosis | 379 (38.1) | 30 (30.0) | 81 (49.1) | |
| Alcoholic cirrhosis | 172 (17.3) | 24 (24.0) | 20 (12.1) | |
| Others | 135 (13.6) | 16 (16.0) | 7 (4.2) | |
| MELD score, median (range) | 14 (3–42) | 19 (7–45) | 22 (7–54) | <0.0001 |
| Medical priority | 0.289 | |||
| Status 1 | 4 (0.4) | 0 (0.0) | 2 (1.2) | |
| Non-status 1 | 991 (99.6) | 100 (100.0) | 163 (98.8) | |
| 1-year mortality | 593 (59.6) | 31 (31.0) | 43 (26.0) | <0.0001 |
SPLT, split liver transplantation; WLT, whole liver transplantation; HBV, hepatitis B virus; HCV, hepatitis C virus; LT, liver transplantation; MELD, Model for End-stage Liver Disease.
Figure 3Comparison of Kaplan–Meier survival curves in patients who underwent split liver transplantation based on the graft weight. Recipients transplanted with a graft weight of ≥580 g had significantly superior survival than the other recipients (p = 0.001).